First, the rash usually occurs 7 to 10 days after the start of treatment, can be self-healing and reproduction, is reversible, with the discontinuation of treatment and disappear. During the appearance of the rash, it is recommended that you bathe with soap that is less irritating to the skin and avoid exposure to the sun. For the rash can generally use some ointment symptomatic treatment, for example, for moderate to severe rash can be applied topically chloramphenicol, Zeomicin, Bactrim, every 5 to 6 hours, alternating between the two. Most patients can adhere to the medication, and if they do, the majority of rashes can turn for the better. If the symptomatic treatment does not see relief can target drugs to consider reducing the amount. Clinically, oral tetracyclines can be taken 50mg, 2 times / day, local application of corticosteroid ointment, 2 times / day. Regardless of whether the rash disappears or not, the treatment should be continued. Emollients, lactic acid, and antihistamines can be applied simultaneously when the rash is severe. The appearance and extent of the rash generally predicts a better outcome. The severity of the rash is positively correlated with the efficacy of trocar. Survival is significantly better in patients with a rash than in those without a rash. Diarrhea is usually mild, and if symptoms are severe, it can be treated symptomatically with some antidiarrheal drugs. Most of the patients can be controlled with loperamide (Emodin). Generally the first dose of 4mg, and then every 2~4 hours with 2mg, has been used until the diarrhea stops, in patients with severe diarrhea (loperamide treatment is ineffective), trocar and other target drugs should be reduced or discontinued. If really can not tolerate the diarrhea caused by trocar, dehydration or skin adverse reactions of patients, can suspend the drug for 14 days, and then resume the drug. Digestive tract symptoms Oral mucositis: can be treated by gargling with Rejuvenate (10 ml 3 times a day). Rehabilitation of new liquid after refrigeration to use the effect is better. Mouth ulcers: Guilin watermelon cream powder spraying the affected area, vitamin B2 water to drink, Bayer sm-33 GEL oral soothing gel, compound chamomile lidocaine gel (Ganymede). Hiccups Acid Reflux: 1:5 Soda Water Take a few sips when acid. You can eat a kiwi to stop it for 1-2 hours, if it doesn’t work you can take baclofen. Anorexia: take Eldridge (megestrol acetate dispersible tablets), megestrol is a hormonal drug, preferably for 7 consecutive days. 160mg per day for 1-2 weeks, not to be taken for a long time. Decrease in appetite: digestive drugs (yeast tablets, multi-enzyme tablets, gastrointestinal tablets, etc.), dexamethasone, the latter has a greater adverse effect. Cardiotoxicity, including left heart failure, hypertension and prolongation of QT interval (QTc). The mechanism of drug-induced left heart failure varies, and molecularly targeted drugs such as trastuzumab produce type II cardiac injury. Angiogenesis inhibitors and MEK inhibitors induce hypertension, and QTc prolongation is a side effect of histone deacetylase inhibitors, ABL inhibitors, MET inhibitors, and multi-target tyrosine kinase inhibitors. Cardiac function should be monitored and compared when using drugs with cardiac impairment, especially in those with a previous history of cardiac disease. Partial dose dependence requires control of the overall dose used and reduction or even discontinuation if necessary. V. Pulmonary toxicity Including acute and subacute pneumonia, alveolar hemorrhage, hemoptysis, pleural leakage, pulmonary arterial hypertension (PAH) and pulmonary embolism. For example (1) Gefitinib, incidence 1%, 30% lethal. Risk factors include advanced age, poor PS score, smoking, shorter time to diagnosis of cancer, reduced normal lung volume on CT, previous history of interstitial lung disease, and concurrent heart disease. (2) Erlotinib, incidence 0, 6%, 30% lethal. (3) mTOR inhibitors: 11% incidence, 3% grade 3-4 pneumonia, usually asymptomatic, low lethality. Treatment consists of discontinuation of the drug, supportive care, and use of corticosteroids in critically ill patients. Gefitinib and erlotinib are reintroduced after discontinuation, either at reduced doses or with concomitant glucocorticoids, and pneumonia may reappear.